In the recently held “Art of Tumor Treatment – Achievement of Future” Researchers Summit Forum, experts from the Collaborative Professional Committee of Clinical Oncology of China Anti-Cancer Association pointed out that once liver cancer is diagnosed, only about 15% of patients can be operated, while the rest can only be treated palliatively. For example, the targeted drug sorafenib for liver cancer is not perfect, and there are mainly 5 problems as follows 1. There is no biomarker to predict its efficacy, i.e., there is no way to know in advance which patients it will be effective for, so there is blindness in the treatment. In this regard, we cannot hope for Sorafenib to treat liver cancer and need to seek other ways. In fact, the efficacy of targeted drugs is largely the same, and the efficacy is very low, so we should not be superstitious in treatment, but also combine Chinese and Western medicine.